MDM2 and neurodegenerative disease: Validation experiments subsequently demonstrated that inhibitors targeting MDM2, ezrin, and cortactin deacetylation could effectively suppress ferroptosis, offering new avenues for mitigating various conditions, such as acute kidney injuries and neurodegenerative diseases, albeit requiring further validation in disease model cells.